Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Status:
Completed
Trial end date:
2018-12-08
Target enrollment:
Participant gender:
Summary
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC)
administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic
migraine (EM). Participants with CM or EM who complete the pivotal efficacy studies of
TEV-48125 (TV48125-CNS-30049 [NCT02621931] and TV48125-CNS-30050 [NCT02629861]) and agree to
participate in this study; and new participants meeting eligibility criteria (not rolling
over from pivotal studies), will be enrolled in this study.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.